Compare BCBP & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | UNCY |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.3M | 150.1M |
| IPO Year | 2005 | 2021 |
| Metric | BCBP | UNCY |
|---|---|---|
| Price | $8.63 | $4.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $8.95 | ★ $29.60 |
| AVG Volume (30 Days) | 368.6K | ★ 767.1K |
| Earning Date | 10-26-2026 | 11-11-2026 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $52,701.90 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.31 | $3.93 |
| 52 Week High | $11.71 | $8.74 |
| Indicator | BCBP | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 40.81 |
| Support Level | $8.50 | $3.93 |
| Resistance Level | $8.91 | $5.86 |
| Average True Range (ATR) | 0.23 | 0.20 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 58.22 | 38.32 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.